[go: up one dir, main page]

WO2006065590A3 - Compositions antivirales a base de pyridines et de pyrimidines - Google Patents

Compositions antivirales a base de pyridines et de pyrimidines Download PDF

Info

Publication number
WO2006065590A3
WO2006065590A3 PCT/US2005/044206 US2005044206W WO2006065590A3 WO 2006065590 A3 WO2006065590 A3 WO 2006065590A3 US 2005044206 W US2005044206 W US 2005044206W WO 2006065590 A3 WO2006065590 A3 WO 2006065590A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine
antiviral compositions
pyrimidine
pyrimidine antiviral
methods
Prior art date
Application number
PCT/US2005/044206
Other languages
English (en)
Other versions
WO2006065590A2 (fr
Inventor
C Richard Wobbe
Original Assignee
Xtl Biopharmaceuticals Inc
C Richard Wobbe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xtl Biopharmaceuticals Inc, C Richard Wobbe filed Critical Xtl Biopharmaceuticals Inc
Publication of WO2006065590A2 publication Critical patent/WO2006065590A2/fr
Publication of WO2006065590A3 publication Critical patent/WO2006065590A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des dérivés pyridines et pyrimidines représentés par la formule (I), dans laquelle R1, R2, R3, R4 et R5 sont tels que définis dans le descriptif de l'invention, et à des compositions pharmaceutiques les contenant, utiles comme composés antiviraux. L'invention a également trait à des procédés de préparation desdits composés et à des procédés d'utilisation de ces derniers comme agents antiviraux dans le cadre d'un traitement.
PCT/US2005/044206 2004-12-16 2005-12-05 Compositions antivirales a base de pyridines et de pyrimidines WO2006065590A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63710804P 2004-12-16 2004-12-16
US60/637,108 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006065590A2 WO2006065590A2 (fr) 2006-06-22
WO2006065590A3 true WO2006065590A3 (fr) 2006-09-21

Family

ID=36337452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044206 WO2006065590A2 (fr) 2004-12-16 2005-12-05 Compositions antivirales a base de pyridines et de pyrimidines

Country Status (1)

Country Link
WO (1) WO2006065590A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
CA2734487A1 (fr) 2008-08-20 2010-02-25 Southern Research Institute Derives de pyridine et de pyrimidine a substitution ethylyle et leur utilisation dans le traitement d'infections virales
CA2734489C (fr) * 2008-08-20 2016-11-08 Southern Research Institute Derives de pyridine et de pyrimidine substitues par ethenyle et leur utilisation dans le traitement d'infections virales
CA2734486A1 (fr) 2008-08-20 2010-02-25 Southern Research Institute Derives de pyridine et pyrimidine substituees et leur utilisation dans le traitement d'infections virales
AU2009282572B2 (en) 2008-08-20 2014-09-11 Merck Sharp & Dohme Corp. Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2671888A1 (fr) 2008-12-23 2013-12-11 Gilead Pharmasset LLC Analogues de nucléoside phosphates 3',5'-cycliques
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
UA122959C2 (uk) 2010-03-31 2021-01-27 Гайлід Фармассет Елелсі Нуклеозидфосфорамідати
EP3038601B1 (fr) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Préparation combinée de deux composés antiviraux
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
TWI751271B (zh) 2017-01-23 2022-01-01 美商凱登製藥公司 鉀離子通道調節子
KR20210080446A (ko) 2018-10-22 2021-06-30 카덴트 테라퓨틱스, 인크. 칼륨 채널 조절제의 결정 형태
JP2023551637A (ja) * 2020-11-06 2023-12-12 ペレメッド カンパニー リミテッド 新規なカプシド組み立て阻害剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078648A2 (fr) * 2000-04-17 2001-10-25 Dong Wha Pharm. Ind. Co., Ltd. Derives de 6-methylnicotinamide utilises comme agents antiviraux
WO2003078427A1 (fr) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines inhibitrices des proteines kinases
WO2003084953A1 (fr) * 2002-04-04 2003-10-16 B & C Biopharm Derives de 6-(anilino-4-substitue)pyrimidine, procede de preparation de ces derives et composition pharmaceutique antivirale les contenant
US20050192294A1 (en) * 2004-02-27 2005-09-01 Bayer Pharmaceuticals Corporation Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078648A2 (fr) * 2000-04-17 2001-10-25 Dong Wha Pharm. Ind. Co., Ltd. Derives de 6-methylnicotinamide utilises comme agents antiviraux
WO2003078427A1 (fr) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines inhibitrices des proteines kinases
WO2003084953A1 (fr) * 2002-04-04 2003-10-16 B & C Biopharm Derives de 6-(anilino-4-substitue)pyrimidine, procede de preparation de ces derives et composition pharmaceutique antivirale les contenant
US20050192294A1 (en) * 2004-02-27 2005-09-01 Bayer Pharmaceuticals Corporation Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROUCHAUD, J. ET AL: "Soil metabolism of flupyrsulfuron in winter wheat crops", WEED RESEARCH , 42(1), 14-25 CODEN: WEREAT; ISSN: 0043-1737, 2002, XP002383028 *
ROUCHAUD, JEAN ET AL: "Flupyrsulfuron Soil Dissipation and Mobility in Winter Wheat Crops", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY , 47(9), 3872-3878 CODEN: JAFCAU; ISSN: 0021-8561, 1999, XP002383029 *
ROUCHAUD, JEAN ET AL: "The cyclization transformation of the sulfonylurea herbicide flupyrsulfuron in the soil of winter wheat crops", PEST MANAGEMENT SCIENCE , 59(8), 940-948 CODEN: PMSCFC; ISSN: 1526-498X, 2003, XP002383027 *
SINGLES, SUZANNE KOCH ET AL: "Fate and behavior of flupyrsulfuron-methyl in soil and aquatic systems", PESTICIDE SCIENCE , 55(3), 288-300 CODEN: PSSCBG; ISSN: 0031-613X, 1999, XP002383030 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
WO2006065590A2 (fr) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2006065590A3 (fr) Compositions antivirales a base de pyridines et de pyrimidines
WO2005123731A3 (fr) Composes organiques
WO2006011050A3 (fr) Derives de pyridine
WO2006021454A3 (fr) Derives de pyrimidine
WO2005110994A8 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
NO20091394L (no) Pyridin-4-yl-derivater som immunmodulerende midler
TW200732323A (en) Organic compounds
PH12012501817A1 (en) Polysubstituted derivatives of 6-heteroaryl-imidazo[1,2-a] pyridines, and preparation and therapeutic use thereof
WO2006126082A3 (fr) Pyridine [3,4-b] pyrazinones
WO2007090141A3 (fr) Composés chimiques
TNSN07074A1 (en) Pyrimidine derivatives
WO2007044724A3 (fr) Inhibiteurs de pim-1 et/ou de pim-3 a base de pyridopyrimidinone
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
TW200606162A (en) Pyrazolopyridine derivatives
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
WO2009016498A8 (fr) Dérivés de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
TW200726758A (en) New pyridine analogues
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
WO2008104473A3 (fr) Inhibiteurs de kinase et procédés d'utilisation de ces derniers
MX2007008237A (es) Compuestos de piridina novedosos.
WO2006010591A3 (fr) Derives de quinazoline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS FF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 05853195

Country of ref document: EP

Kind code of ref document: A2